Patents by Inventor Hidekazu Inoue

Hidekazu Inoue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11034659
    Abstract: Cystic fibrosis is developed through mutation of Cystic Fibrosis Transmembrane conductance Regulator (CFTR), which is one type of chloride channel. An object of the present invention is to provide compounds effective in the treatment of cystic fibrosis that open a chloride channel different from CFTR, which is the cause of the disease, and do not depend on CFTR. Compounds of the present invention are compounds or pharmaceutically acceptable salts thereof that open calcium dependent chloride channels (CaCCs) via G-protein coupled receptor 39 (GPR39) agonism to have strong chloride ion-secretory action, and are represented by the following general formula (I): General formula (I): wherein, X represents a carboxyl group or a tetrazolyl group; Q represents a C1-C3 alkylene group, an oxygen atom, a sulfur atom, etc.; G represents a phenyl group where the phenyl group may have 1 to 3 substituents independently selected from the group consisting of a halogen atom, a cyano group, a C1-C6 alkyl group, etc.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: June 15, 2021
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yasuyuki Takeda, Yamato Suzuki, Toshiharu Noji, Hidenobu Murafuji, Satoshi Muneoka, Hidekazu Inoue, Bitoku Takahashi, Rie Inaba
  • Patent number: 10774087
    Abstract: Provided is a novel compound or a salt thereof inhibiting MTHFD2 and useful for treating a disease caused by overexpression of MTHFD2, a disease involved in overexpression of MTHFD2 and/or a disease associated with overexpression of MTHFD2. Solution Provided is a sulfonamide derivative having a coumarin skeleton represented by the following formula (I) and having various substituents: wherein R1, R2, R3, R4, R5, R6 and R7 are the same as defined in the specification, and a salt thereof.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: September 15, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Masahiro Ota, Hidekazu Inoue, Junya Kawai, Hitoshi Ohki, Tadashi Toki
  • Publication number: 20200172494
    Abstract: Cystic fibrosis is developed through mutation of Cystic Fibrosis Transmembrane conductance Regulator (CFTR), which is one type of chloride channel. An object of the present invention is to provide compounds effective in the treatment of cystic fibrosis that open a chloride channel different from CFTR, which is the cause of the disease, and do not depend on CFTR. Compounds of the present invention are compounds or pharmaceutically acceptable salts thereof that open calcium dependent chloride channels (CaCCs) via G-protein coupled receptor 39 (GPR39) agonism to have strong chloride ion-secretory action, and are represented by the following general formula (I): General formula (I): wherein, X represents a carboxyl group or a tetrazolyl group; Q represents a C1-C3 alkylene group, an oxygen atom, a sulfur atom, etc.; G represents a phenyl group where the phenyl group may have 1 to 3 substituents independently selected from the group consisting of a halogen atom, a cyano group, a C1-C6 alkyl group, etc.
    Type: Application
    Filed: December 26, 2017
    Publication date: June 4, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yasuyuki Takeda, Yamato Suzuki, Toshiharu Noji, Hidenobu Murafuji, Satoshi Muneoka, Hidekazu Inoue, Bitoku Takahashi, Rie Inaba
  • Publication number: 20190284198
    Abstract: Provided is a novel compound or a salt thereof inhibiting MTHFD2 and useful for treating a disease caused by overexpression of MTHFD2, a disease involved in overexpression of MTHFD2 and/or a disease associated with overexpression of MTHFD2. Solution Provided is a sulfonamide derivative having a coumarin skeleton represented by the following formula (I) and having various substituents: wherein R1, R2, R3, R4, R5, R6 and R7 are the same as defined in the specification, and a salt thereof.
    Type: Application
    Filed: November 22, 2017
    Publication date: September 19, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Masahiro Ota, Hidekazu Inoue, Junya Kawai, Hitoshi Ohki, Tadashi Toki
  • Patent number: 9464076
    Abstract: Compounds having PDE10A inhibitory activity and having general formula (I), or an isotope thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 11, 2016
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hidekazu Inoue, Yoshito Kawamoto, Katsuhide Kamei, Kenichi Hiramatsu, Minako Tomino
  • Publication number: 20160024060
    Abstract: [Problem to be Solved] It is intended to provide a compound having PDE10A inhibitory activity and having a novel structure, or an isotope thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. [Solution] The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Hidekazu Inoue, Yoshito Kawamoto, Katsuhide Kamei, Kenichi Hiramatsu, Minako Tomino
  • Patent number: 8901315
    Abstract: To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R2 is methyl; R3 is a hydrogen atom; and R4 is a group: —CONR5R6 (in which any one of R5 and R6 is a hydrogen atom)].
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: December 2, 2014
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hidekazu Inoue, Hidenobu Murafuji, Yasuhiro Hayashi
  • Publication number: 20140073799
    Abstract: To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R2 is methyl; R3 is a hydrogen atom; and R4 is a group: —CONR5R6 (in which any one of R5 and R6 is a hydrogen atom)].
    Type: Application
    Filed: August 29, 2013
    Publication date: March 13, 2014
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hidekazu INOUE, Hidenobu Murafuji, Yasuhiro Hayashi
  • Publication number: 20120146924
    Abstract: An electronic apparatus includes a display configured to display an image, a liquid detection unit configured to detect liquid on a surface of the display, and a display control unit configured to change a display mode of the display based on the detection of liquid on the surface of the display by the liquid detection unit.
    Type: Application
    Filed: November 21, 2011
    Publication date: June 14, 2012
    Applicant: Sony Corporation
    Inventor: Hidekazu Inoue
  • Publication number: 20110166343
    Abstract: To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R2 is methyl; R3 is a hydrogen atom; and R4 is a group: —CONR5R6 (in which any one of R5 and R6 is a hydrogen atom)].
    Type: Application
    Filed: March 14, 2011
    Publication date: July 7, 2011
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hidekazu Inoue, Hidenobu Murafuji, Yasuhiro Hayashi
  • Patent number: 7943624
    Abstract: To provide the compounds inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is pyridinylpyrazolo-pyrimidinone compound represented by the following formula (IA) or (IB): especially, R1 is cyclohexyl or cycloheptyl group, R2 is methyl; R3 is a group: —NR5R6 or —S(O)0-2R8;hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; and R4 is methoxy or ethoxy group.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: May 17, 2011
    Assignee: Asubio Pharma Co. Ltd.
    Inventors: Hidekazu Inoue, Hidenobu Murafuji, Yasuhiro Hayashi
  • Patent number: 7932250
    Abstract: To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R2 is methyl; R3 is a hydrogen atom; and R4 is a group: —CONR5R6 (in which any one of R5 and R6 is a hydrogen atom)].
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: April 26, 2011
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hidekazu Inoue, Hidenobu Murafuji, Yasuhiro Hayashi
  • Patent number: 7713972
    Abstract: The present invention provides the compounds inhibiting PDE 7 selectively, and therefore, enhances cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is imidazotriazinone compound represented by the following formula (IA) or (IB): especially, R1 is cyclohexyl group, R2 is methyl group; R3 is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C1-C6 alkyl group; substituted or unsubstituted C2-C6 alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: —NR5R6, —C(O)R7, —SO2R7, —OR8, —NR8COR7, —NR8S02R7; A is CR4; and B is CH.
    Type: Grant
    Filed: June 11, 2004
    Date of Patent: May 11, 2010
    Assignee: Asubio Pharma Co., Ltd.
    Inventors: Hidekazu Inoue, Hidenobu Murafuji, Yasuhiro Hayashi
  • Patent number: 7698107
    Abstract: A substrate processing apparatus and an information storage server are connected with each other through a network. A storage part of the substrate processing apparatus stores set information and a control program, for controlling operation of the substrate processing apparatus according to the set information and the control program. The substrate processing apparatus is provided with a schedule function, for transmitting a backup instructional command according to the schedule. In response to this instructional command, the substrate processing apparatus generates a duplicate of specified information stored in the aforementioned storage part and transfers the duplicate information to the information storage server through the network. The information storage server stores the received duplicate information in a hard disk as backup data. The information storage server can also store only differential data of the duplicate information.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: April 13, 2010
    Assignee: Dainippon Screen Mfg. Co., Ltd.
    Inventors: Toru Kitamoto, Kenji Kamei, Hidekazu Inoue, Tetsuya Hamada
  • Publication number: 20090131413
    Abstract: To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R2 is methyl; R3 is a hydrogen atom; and R4 is a group: —CONR5R6 (in which any one of R5 and R6 is a hydrogen atom)].
    Type: Application
    Filed: July 1, 2005
    Publication date: May 21, 2009
    Applicant: ASUBIO PHARMA CO., LTD.
    Inventors: Hidekazu Inoue, Hidenobu Murafuji, Yasuhiro Hayashi
  • Publication number: 20090051428
    Abstract: This invention offers an AGC circuit that prevents disturbance in an output waveform when an input signal varies abruptly. A first terminal of a capacitor is connected with an output terminal of a variable gain amplifier and a second terminal of the capacitor is connected with a non-inverting input terminal (+) of a differential amplifier. A reference voltage Vref2 is applied to an inverting input terminal (?) of the differential amplifier. A bias voltage Vbias from a bias circuit is applied to the non-inverting input terminal (+) of the differential amplifier, while the reference voltage Vref2 from the bias circuit is applied to the inverting input terminal (?) of the differential amplifier. An output signal of the differential amplifier is applied to the variable gain amplifier through a direct current amplifier as a direct current control voltage.
    Type: Application
    Filed: October 29, 2007
    Publication date: February 26, 2009
    Applicants: Sanyo Electric Co., Ltd., Sanyo Semiconductor Co., Ltd.
    Inventors: Keiji AMEMIYA, Hidekazu INOUE
  • Patent number: 7460923
    Abstract: A substrate processing system comprises a substrate processing apparatus, an information storage server and a support computer, which are connected to a network respectively. When the substrate processing apparatus causes a failure, an alarm processing part extracts a necessary relevant log file and stores the same in a hard disk of the information storage server. A failure information generation part generates failure information, which in turn is finally stored in the hard disk of the information storage servers as a failure information database. An apparatus information uncasing part renders the relevant log file and the failure information database readable from the support computer located in a remote place. Thus, the relevant log file and the failure information database can be immediately read. In other words, provided is a substrate processing system rendering operation information immediately readable from a remote place when the substrate processing apparatus causes a failure.
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: December 2, 2008
    Assignee: Dainippon Screen Mfg. Co., Ltd.
    Inventors: Toru Kitamoto, Kenji Kamei, Hidekazu Inoue, Tetsuya Hamada
  • Patent number: 7407712
    Abstract: It is an object of the present invention to provide a release film which is superior in the flexibility at high temperature, the conformability to circuit patterns, the heat resistance, the releasing property and the non-contaminative property, and easily discarded after use. The present invention relates to a release film, which is used in a manufacturing process of a printed-circuit board, a flexible printed-circuit board or a multilayer printed-circuit board, having a layer comprising a resin composition comprising a resin having a polar group in a main chain as a matrix and having a halogen content of 5% by weight or less on at least one surface.
    Type: Grant
    Filed: December 26, 2003
    Date of Patent: August 5, 2008
    Assignee: Sekisui Chemical Co., Ltd.
    Inventors: Hirotake Matsumoto, Hitoshi Shirato, Hidekazu Inoue
  • Patent number: 7333867
    Abstract: A substrate processing system comprises a substrate processing apparatus and a support computer, which are connected to a network respectively. Updated countermeasure information is accumulated in the support computer by a system administrator. When the substrate processing apparatus causes a failure, content of the failure is displayed on a display part while an alarm processing part controls process according to an alarm definition file. Further, a countermeasure information acquisition part requires updated countermeasure information against the failure from the support computer. In response to this, countermeasure information distribution part of the support computer transmits updated countermeasure information. Thus, updated countermeasure information can be read instantly when a failure occurs.
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: February 19, 2008
    Assignee: Dainippon Screen Mfg. Co., Ltd.
    Inventors: Toru Kitamoto, Kenji Kamei, Hidekazu Inoue, Tetsuya Hamada
  • Patent number: 7318081
    Abstract: A band-pass filter includes two operational amplifiers. The gm values of the operational amplifiers are each determined by a current flowing through a corresponding transistor for inducing flow of the drive current. The current flowing through the transistor is adjusted by zapping.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: January 8, 2008
    Assignee: Sanyo Electric Co., Ltd.
    Inventor: Hidekazu Inoue